The American Thoracic Society/European Respiratory Society jointly created a Task Force
on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform …

Dyspnea is a primary symptom of chronic lung disease and an important outcome measure
for clinical trials. Several standardized measures have been developed to evaluate this …

Expiratory flow limitation (EFL) during tidal breathing is a major determinant of dynamic
hyperinflation and exercise limitation in chronic obstructive pulmonary disease (COPD) …

Fashions in ideas, like clothes, come and go. From approximately 1950–1980, physiological
research was seen as the key discipline in understanding lung disease and was at the …

Introduction Exertional dyspnoea is the primary diagnostic symptom for chronic
cardiopulmonary disease populations. Whilst a number of exercise tests are used, there …

This study examined the effects of bronchodilator-induced reductions in lung hyperinflation
on breathing pattern, ventilation and dyspnoea during exercise in chronic obstructive …

Background: Chronic obstructive pulmonary disease (COPD) is a syndrome of chronic
progressive airflow limitation which occurs as a result of chronic inflammation of the airways …

This real-world study evaluated the efficacy of once-daily long-acting β2-agonist
(LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) for …

Expiratory flow limitation (EFL) is present when the flow cannot rise despite an increase in
the expiratory driving pressure. The mechanisms of EFL are debated but are believed to be …

It has been shown that patients with chronic obstructive pulmonary disease (COPD) develop
dynamic hyperinflation (DH), which contributes to dyspnoea and exercise intolerance …